Danicopan (Synonyms: ACH-4471) CAS No.: 1903768-17-1

Danicopan (Synonyms: ACH-4471) CAS No.: 1903768-17-1

Chemical Structure : Danicopan  (Synonyms: ACH-4471)
CAS No.: 1903768-17-1

Description

Chemical Structure : Danicopan (Synonyms: ACH-4471)

CAS No.: 1903768-17-1

product-600-600

 

Danicopan (Synonyms: ACH-4471)

Catalog No.: URK-V2534 Only Used For Lab.

Danicopan (ACH-4471) is an effective and selective inhibitor of complement factor D, with an IC50 value of 0.6 nM.

 

Biological Activity

Danicopan(ACH-4471) is an effective and selective inhibitor of complement factor D, with an IC50 value of 0.6 nM. Complement factor D is a serine protease that cleaves factor B, which activates the alternative complement pathway.
Danicopan(ACH-4471) has been demonstrated to inhibit the alternative complement pathway in vitro and in vivo, leading to reduced C3 deposition. In addition, danicopan has been shown to have favorable pharmacokinetic properties and demonstrate dose-dependent inhibition of factor D activity in healthy human subjects.
Danicopan is currently being investigated for various indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, and geographic atrophy. In a phase 2 clinical trial for patients with paroxysmal nocturnal hemoglobinuria, danicopan demonstrated a significant reduction in hemolysis and increased hemoglobin levels compared to placebo. Additionally, a phase 2 clinical trial for C3 glomerulopathy showed a reduction in proteinuria and increased eGFR in patients treated with danicopan.

 

Physicochemical Properties

M.Wt

580.41

Formula

C26H23BrFN7O3

CAS No.

1903768-17-1

Appearance

Solid

Storage

Solide Powder

-20 °C 3years;

4°C 2years

In Solvent

-80°C 6 Months

-20°C 1 Months

Solubility

 

Chemical Name

 

 

References

1. Ricklin D, et al. Complement-targeted therapeutics. Nat Biotechnol. 2017;35(9):833-847.

 

2. Risitano AM, et al. Danicopan: a review of preclinical and clinical data. Expert Rev Hematol. 2021;14(1):17-29.

 

3. Risitano AM, et al. A phase 2 study of the oral complement inhibitor danicopan for paroxysmal nocturnal hemoglobinuria. Blood. 2019;133(9):966-975.

 

4. Bomback AS, et al. Efficacy and safety of the oral complement inhibitor danicopan in C3 glomerulopathy. J Am Soc Nephrol. 2021;32(4):929-941.

 

product-80-80

URK-V2534_COA

product-80-80

URk-V2534_SDS

product-80-80

URK-V2534_TDS

Hot Tags: Danicopan (Synonyms: ACH-4471) CAS No.: 1903768-17-1, China Danicopan (Synonyms: ACH-4471) CAS No.: 1903768-17-1, agonists for pharmacodynamics, epigenetic library for epigenetic analysis of gene function, epigenetic library for epigenetic regulation of cell differentiation, inhibitors for scar formation, epigenetic library for epigenetic analysis of dna methylation, epigenetic library for epigenetic determination of cell identity

You Might Also Like

Shopping Bags